The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse and CD19-negative relapses was highlighted, emphasizing the importance of continued IT chemotherapy.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
While there is interest in reducing systemic chemotherapy, caution was advised due to potential resistance. The potential of combining antigen-directed therapies with chemotherapy for better coverage was discussed, along with the need for longer-term follow-up to assess treatment outcomes.